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BACKGROUND
Nusinersen is an antisense oligonucleotide drug that modulates pre–messenger 
RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed 
for the treatment of spinal muscular atrophy (SMA).
METHODS
We conducted a multicenter, double-blind, sham-controlled, phase 3 trial of nusin-
ersen in 126 children with SMA who had symptom onset after 6 months of age. 
The children were randomly assigned, in a 2:1 ratio, to undergo intrathecal admin-
istration of nusinersen at a dose of 12 mg (nusinersen group) or a sham procedure 
(control group) on days 1, 29, 85, and 274. The primary end point was the least-
squares mean change from baseline in the Hammersmith Functional Motor Scale–
Expanded (HFMSE) score at 15 months of treatment; HFMSE scores range from 
0 to 66, with higher scores indicating better motor function. Secondary end points 
included the percentage of children with a clinically meaningful increase from 
baseline in the HFMSE score (≥3 points), an outcome that indicates improvement 
in at least two motor skills.
RESULTS
In the prespecified interim analysis, there was a least-squares mean increase from 
baseline to month 15 in the HFMSE score in the nusinersen group (by 4.0 points) 
and a least-squares mean decrease in the control group (by –1.9 points), with a 
significant between-group difference favoring nusinersen (least-squares mean dif-
ference in change, 5.9 points; 95% confidence interval, 3.7 to 8.1; P<0.001). This 
result prompted early termination of the trial. Results of the final analysis were 
consistent with results of the interim analysis. In the final analysis, 57% of the 
children in the nusinersen group as compared with 26% in the control group had 
an increase from baseline to month 15 in the HFMSE score of at least 3 points 
(P<0.001), and the overall incidence of adverse events was similar in the nusinersen 
group and the control group (93% and 100%, respectively).
CONCLUSIONS
Among children with later-onset SMA, those who received nusinersen had sig-
nificant and clinically meaningful improvement in motor function as compared 
with those in the control group. (Funded by Biogen and Ionis Pharmaceuticals; 
CHERISH ClinicalTrials.gov number, NCT02292537.)
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Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disor-der that is characterized by atrophy and 
weakness of the skeletal muscles of the limbs 
and trunk and of the bulbar and respiratory 
muscles.1,2 It is caused by homozygous deletions 
or loss-of-function mutations in the gene encod-
ing survival motor neuron 1 (SMN1) at locus 
5q13, which result in insufficient expression of 
the survival motor neuron (SMN) protein.1,3-5 A 
paralogous gene, SMN2, also encodes the SMN 
protein, but the level of functional full-length 
SMN protein produced by SMN2 is only 5 to 10% 
of the level produced by SMN1, because a splice-
site variant in SMN2 leads to exclusion of exon 
7 from the mature RNA transcript and produc-
tion of truncated, dysfunctional SMN protein.5,6 
Nusinersen is a modified antisense oligonucleo-
tide drug that resists nucleases and binds to a 
specific sequence within the SMN2 pre–messen-
ger RNA, thereby modifying the splicing of the 
SMN2 pre–messenger RNA to promote the ex-
pression of full-length SMN protein.7-10
The classification system for SMA is based 
on the age at symptom onset and the most ad-
vanced motor milestone attained during devel-
opment.5 Patients with a higher SMN2 copy 
number and a higher level of SMN protein 
generally have a less severe phenotype.11,12 SMA 
type 1 is characterized by symptom onset by 
6 months of age and failure to sit without sup-
port, SMA type 2 by symptom onset between 
6 and 18 months of age and failure to walk 
independently, and SMA type 3 by symptom 
onset after 18 months of age and an ability to 
walk independently at some point.1,2,5,6,13,14 
However, these motor milestones can be lost 
over time.5,15,16 In this trial, we defined later-
onset SMA as disease with symptom onset after 
6 months of age (most likely to be classified as 
SMA type 2 or 3).5 Two earlier open-label trials 
and their extensions showed that the adminis-
tration of nusinersen did not raise safety con-
cerns and had a benefit with respect to motor 
function in children with SMA type 2 or 3.9,17 
We therefore conducted the multicenter, ran-
domized, double-blind, sham-controlled, phase 3 
CHERISH trial to evaluate the efficacy and 
safety of nusinersen in children with later- 
onset SMA.
Me thods
Trial Oversight
The CHERISH trial protocol (available with the 
full text of this article at NEJM.org) was ap-
proved by the independent review board or eth-
ics committee at each participating site and was 
conducted according to the provisions of the 
Declaration of Helsinki and the International 
Conference on Harmonisation Good Clinical 
Practice guidelines. The parents or legal guard-
ians of eligible children provided written in-
formed consent before participation; the children 
provided assent as appropriate, on the basis of 
institutional guidelines and the child’s age. In 
collaboration with the sponsors (Biogen and Ionis 
Pharmaceuticals), an independent data and safe-
ty monitoring board reviewed safety data at 
quarterly intervals, including the results of the 
prespecified interim analysis.
The trial was designed by employees of the 
sponsors in collaboration with clinicians who 
had experience in the treatment of SMA. Investi-
gators collected the data, which were held and 
analyzed by Biogen. The authors had access to 
the complete data set after unblinding, partici-
pated in data analysis and interpretation and in 
manuscript development, and vouch for the ac-
curacy and completeness of the data. The princi-
pal investigators vouch for the fidelity of the 
study to the protocol and protocol amendments. 
The first draft of the manuscript was written by 
the first author and the senior industry author 
from Biogen; medical-writing assistance was paid 
for by Biogen. The sponsors reviewed the manu-
script and provided feedback to the authors, who 
had full editorial control and approved the final 
manuscript for submission.
Patients
Key eligibility criteria were genetic documenta-
tion of 5q SMA (a homozygous deletion, mutation, 
or compound heterozygote in SMN1) with symp-
tom onset after 6 months of age, as well as the 
presence of the following features at screening: 
an age of 2 to 12 years, the ability to sit indepen-
dently, no history of the ability to walk inde-
pendently (defined as the ability to walk ≥15 ft 
unaided), and a Hammersmith Functional Motor 
Scale–Expanded (HFMSE) score of 10 to 54. 
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HFMSE scores range from 0 to 66, with higher 
scores indicating better motor function.18,19 Chil-
dren were not eligible for inclusion in the trial if 
they had a severe contracture (i.e., any contrac-
ture that could interfere with assessment of the 
HFMSE score, according to the investigator), evi-
dence of severe scoliosis on radiography (i.e., 
spine curvature with a Cobb angle of >40 de-
grees), respiratory insufficiency (i.e., receipt of 
invasive or noninvasive ventilation for >6 hours 
during a 24-hour period), or a gastric tube placed 
to provide adequate nutrition (see the Supple-
mentary Appendix, available at NEJM.org).
Trial Design and Treatment
The trial was conducted at 24 sites in 10 coun-
tries and was designed to have a screening pe-
riod of 4 weeks, a treatment period of 9 months, 
and a follow-up period of 6 months. To ensure 
balance across the trial groups, the children 
were stratified according to age at screening 
(<6 years vs. ≥6 years) and then were randomly 
assigned, in a 2:1 ratio, to undergo intrathecal 
administration of nusinersen at a dose of 12 mg 
(nusinersen group) or a sham procedure (control 
group). Randomization was performed with the 
use of an interactive Web response system. 
Nusinersen was administered or the sham pro-
cedure was performed by dedicated personnel 
who were aware of the group assignments; the 
child’s parents and key trial personnel who per-
formed assessments were unaware of the group 
assignments until trial completion and were not 
present for the procedure. Participants were se-
dated to avoid any awareness of the procedure. 
Treatments that were considered to be necessary 
to manage adverse events or provide supportive 
care were permitted, in accordance with standard-
of-care guidelines.20
Trial Procedures and End Points
Nusinersen was administered intrathecally on 
days 1, 29, and 85, and a maintenance dose was 
administered on day 274. The sham procedure 
was performed on the same days; it consisted of 
a small needle prick to the lower back, which 
was covered with a bandage to simulate the 
appearance of a lumbar puncture. Children 
were observed at the trial site for at least 24 
hours after the first procedure was performed 
and for at least 6 hours after each procedure 
thereafter.
The primary end point was the least-squares 
mean change from baseline in the total HFMSE 
score at month 15. Trained clinical evaluators21 
assessed the HFMSE score twice during the 
screening period and at 3, 6, 9, 12, and 15 
months. The HFMSE is a 33-item measure of 
motor function that is specifically validated for 
use in patients with SMA to assess activities re-
lated to daily living.2,18,19,21,22 Each of the 33 activi-
ties is scored on a scale ranging from 0 (no re-
sponse) to 2 (full response), and total HFMSE 
scores range from 0 to 66 points, with an in-
crease in total score indicating an improvement 
in motor function.19 A change in the HFMSE 
score of at least 3 points is considered to be 
clinically meaningful.23
The trial had six secondary end points, in-
cluding the percentage of children who had an 
increase from baseline to month 15 in the 
HFMSE score of at least 3 points, the percentage 
of children who achieved at least one new World 
Health Organization (WHO) motor milestone 
(out of a total of six milestones),24 and the 
change from baseline in the Revised Upper Limb 
Module (RULM) score (which ranges from 0 to 
37, with higher scores indicating better func-
tion).25 Safety was evaluated throughout the trial 
(see the Supplementary Appendix).
Statistical Analysis
We estimated that a sample size of 117 children 
would give the trial at least 90% power to detect 
a mean (±SD) difference of 3±4.4 points between 
trial groups in the change from baseline in the 
HFMSE score, at a two-sided alpha level of 0.05. 
To control the overall type I error rate at 0.05 
across the interim and final analyses for the 
primary and secondary end points, a hierarchi-
cal strategy with independent alpha spending 
functions for primary and secondary end points 
was applied26 (see the Supplementary Appendix). 
Because the P value for the primary end point 
was significant in the interim analysis, this end 
point was not formally tested for significance 
in the final analysis. All secondary efficacy end 
points were assessed in the final analysis.
The prespecified interim analysis of the pri-
mary end point was performed in the intention-
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to-treat population, which included patients who 
were randomly assigned to a group and under-
went at least one assigned procedure (Fig. S1 in 
the Supplementary Appendix); this analysis was 
conducted when all the children had been en-
rolled for at least 6 months and at least 39 chil-
dren had completed their 15-month assessment. 
Because some children would not have com-
pleted the 15-month assessment by the time of 
the interim analysis, the analysis was performed 
with the use of a multiple-imputation method to 
account for missing data on HFMSE scores ob-
tained after baseline. Least-squares mean values 
are reported. In the final analysis, the least-
squares mean changes in the total HFMSE score, 
the number of WHO motor milestones achieved 
per child, and the RULM score and least-squares 
mean differences in change between groups were 
based on an analysis of covariance, with group 
assignment as a fixed effect and with adjustment 
for each child’s age at screening and the value at 
baseline.
R esult s
Patients
A total of 179 children were screened; 126 were 
enrolled in the trial, were randomly assigned to 
a group, and underwent the assigned procedure 
(84 in the nusinersen group, and 42 in the con-
trol group) (Fig. S2 in the Supplementary Appen-
dix). The first child underwent the first assigned 
procedure on November 24, 2014, and the last 
child’s last visit occurred on February 20, 2017. 
At the data cutoff date for the prespecified in-
terim analysis (August 31, 2016), 54 children 
(43%) had completed the 15-month assessment 
and all the children had an HFMSE score that 
had been obtained at 6 months or later. In the 
prespecified interim analysis, nusinersen showed 
efficacy superior to that of the sham procedure; 
at the recommendation of the data and safety 
monitoring board, we stopped the trial early. All 
the children who had not had a 15-month assess-
ment were invited to attend a visit that repre-
sented the end of the double-blind period; at this 
visit, all assessments that had been scheduled 
for the 15-month assessment were performed. 
Children who completed the CHERISH trial were 
invited to enroll in the open-label extension study 
(ClinicalTrials.gov number, NCT02594124), in 
which all children were to receive nusinersen.
At the time of the final analysis, no child had 
been withdrawn from the trial. A total of 66 
children (79%) in the nusinersen group and 34 
(81%) in the control group had completed the 
15-month assessment; 26 children were enrolled 
in the open-label extension study early. At the 
15-month assessment or the visit that repre-
sented the end of the double-blind period, all the 
children had undergone the four assigned proce-
dures, except for 1 child who had received only 
three doses of nusinersen before the trial ended 
(Fig. S2 in the Supplementary Appendix). The 
demographic characteristics of the children at 
baseline were similar in the two trial groups; 
there were slight differences in age, sex, race, 
disease duration, and motor milestones achieved, 
but no formal statistical testing was performed. 
The stratum that included children younger than 
6 years of age was larger than the stratum that 
included children 6 years of age or older. A 
higher percentage of children in the control 
group than in the nusinersen group had achieved 
weight-bearing motor milestones, including the 
ability to stand alone or walk with support 
(Table 1, and Table S1 in the Supplementary 
Appendix).
Efficacy
Primary End Point
In the prespecified interim analysis, there was 
a least-squares mean increase from baseline to 
month 15 in the HFMSE score in the nusinersen 
group and a least-squares mean decrease in the 
control group, resulting in a significant between-
group difference favoring nusinersen (least-
squares mean difference in change, 5.9 points; 
95% confidence interval [CI], 3.7 to 8.1; P<0.001) 
(Table 2). In the final analysis, there was a least-
squares mean increase from baseline to month 
15 in the HFMSE score in the nusinersen group 
and a least-squares mean decrease in the control 
group (least-squares mean difference in change, 
4.9 points; 95% CI, 3.1 to 6.7) (Table 2 and 
Fig. 1A). Similar results favoring nusinersen 
were observed in all sensitivity analyses for the 
primary end point and across subgroups defined 
according to SMN2 copy number (Tables S2 and 
S3 in the Supplementary Appendix).
Greater improvements in total HFMSE score 
were observed in the nusinersen group than in 
the control group at time points starting after 
month 6 (Fig. 1A). At month 15, the greatest 
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increases from baseline in the HFMSE score had 
occurred in the nusinersen group, and the greatest 
decreases had occurred in the control group, with 
generally similar results observed at months 9 
and 12 (Fig. S3 in the Supplementary Appendix).
Secondary End Points
A higher percentage of children in the nusinersen 
group than in the control group had an increase 
from baseline to month 15 in the HFMSE score 
of at least 3 points (57% vs. 26%, P<0.001) (Ta-
ble 2, and Fig. S4 in the Supplementary Appen-
dix). The percentage of children who achieved at 
least one new WHO motor milestone did not 
differ significantly between the nusinersen group 
and the control group (20% and 6%, respec-
tively) (Table 2). Because the P value for the 
second secondary end point was not significant, 
all subsequent analyses of end points in the hier-
archical testing strategy were considered to be 
exploratory and are not reported. At month 15, 
there was a least-squares mean increase from 
baseline in the number of new WHO motor 
milestones achieved per child in the nusinersen 
group (by 0.2) and a least-squares mean decrease 
in the control group (by –0.2). There was a least-
squares mean increase from baseline in the 
RULM score in the nusinersen group and in the 
control group (by 4.2 points and 0.5 points, re-
spectively) (Table 2 and Fig. 1B). The greatest 
increases in the RULM score were observed in 
the nusinersen group (Fig. S5 in the Supplemen-
tary Appendix). The proportion of children who 
had achieved the ability to stand alone or walk 
with assistance did not differ significantly be-
tween groups (Table 2). Analyses of the change 
from baseline to month 15 in the HFMSE score 
according to age and disease duration revealed 
greater improvements in younger children and 
in those who received treatment earlier in their 
disease course, respectively (Fig. 2). Results of 
analyses according to geographic region were 
generally consistent with the overall results 
(Table S4 in the Supplementary Appendix).
Safety
The overall incidence of adverse events was 
similar in the nusinersen group and the control 
group (93% and 100%, respectively), as was the 
incidence of moderate or severe adverse events 
(Table 3). Serious adverse events were reported 
in 17% of the children in the nusinersen group 
and in 29% in the control group. Some of the 
events that were reported as adverse events could 
plausibly be linked to SMA and may not reflect 
adverse drug effects (Table 3). No child discon-
tinued treatment or was withdrawn from the 
trial because of an adverse event. The incidences 
of pyrexia, headache, vomiting, back pain, and 
Characteristic
Nusinersen 
(N = 84)
Control 
(N = 42)
Female sex — no. (%) 46 (55) 21 (50)
Age at screening — yr
Median 4.0 3.0
Range 2−9 2−7
Age at symptom onset — mo
Median 10.0 11.0
Range 6−20 6−20
Age at diagnosis of SMA — mo
Median 18.0 18.0
Range 0−48 0−46
Disease duration — mo†
Median 39.3 30.2
Range 8−94 10−80
SMN2 copy number — no. (%)
2 6 (7) 4 (10)
3 74 (88) 37 (88)
4 2 (2) 1 (2)
Unknown 2 (2) 0
Motor milestones ever achieved — no. (%)‡
Ability to sit without support 84 (100) 42 (100)
Ability to walk with support 20 (24) 14 (33)
Ability to walk independently, ≥15 ft 0 0
HFMSE score§ 22.4±8.3 19.9±7.2
WHO motor milestones achieved¶ 1.4±1.0 1.5±1.0
RULM score‖ 19.4±6.2 18.4±5.7
*  Plus–minus values are means ±SD. No formal statistical testing was performed 
to assess differences between trial groups in baseline characteristics. Percent­
ages may not total 100 because of rounding. SMA denotes spinal muscular 
atrophy.
†  Disease duration is a child’s age at screening minus the age at symptom onset.
‡  These data do not reflect the maximal milestone achieved.
§  Hammersmith Functional Motor Scale–Expanded (HFMSE) scores range from 
0 to 66, with higher scores indicating better motor function.19
¶  The six World Health Organization (WHO) motor milestones are sitting with­
out support, standing with assistance, hands and knees crawling, walking with 
assistance, standing alone, and walking alone.24
‖  Revised Upper Limb Module (RULM) scores range from 0 to 37, with higher 
scores indicating better function.25
Table 1. Characteristics of the Patients at Baseline.*
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End Point
Nusinersen 
(N = 84)
Control 
(N = 42) Difference P Value
Interim analysis†
Primary end point: change from baseline in HFMSE score — 
least­squares mean (95% CI)‡
4.0 (2.9 to 5.1) –1.9 (–3.8 to 0) 5.9 (3.7 to 8.1) <0.001
Final analysis§
Primary end point: change from baseline in HFMSE score — 
least­squares mean (95% CI)‡
3.9 (3.0 to 4.9) –1.0 (–2.5 to 0.5) 4.9 (3.1 to 6.7) —
Secondary end points
Children with change in HFMSE score of ≥3 points
% (95% CI)¶ 57 (46 to 68) 26 (12 to 40) 30.5 (12.7 to 48.3)
Odds ratio (95% CI) — — 6 (2 to 15)‖ <0.001
Children who achieved ≥1 new WHO motor milestone
No. 13 2 — —
% (95% CI)** 20 (11 to 31) 6 (1 to 20) 14 (−7 to 34) 0.08
Change from baseline in number of WHO motor mile­
stones achieved — least­squares mean (95% CI)‡
0.2 (0.1 to 0.3) −0.2 (−0.4 to 0) 0.4 (0.2 to 0.7) —
Change from baseline in RULM score — least­squares 
mean (95% CI)‡
4.2 (3.4 to 5.0) 0.5 (−0.6 to 1.6) 3.7 (2.3 to 5.0) —
Children who achieved ability to stand alone
No. 1 1 — —
% (95% CI)** 2 (0 to 8) 3 (0 to 15) −1 (−22 to 19) —
Children who achieved ability to walk with assistance
No. 1 0 — —
% (95% CI)** 2 (0 to 8) 0 (0 to 10) 2 (−19 to 22) —
*  To control the overall type I error rate at 0.05 across the interim and final analyses for the testing of primary and secondary end points,  
a hierarchical strategy was used, in which significance of the primary end point was required before inferential conclusions could be drawn 
about the secondary end points. If an end point failed to reach significance, subsequent end points were not tested within the hierarchi­
cal analysis. Secondary end points are listed in hierarchical order. Because the P value for the second secondary end point was not signifi­
cant, all subsequent end points analyzed in the hierarchical testing strategy were considered to be exploratory. (Details are provided in the 
Supplementary Appendix.)
†  The interim analysis of the primary end point was conducted when all the children had been enrolled for at least 6 months and at least  
39 children had completed the 15­month assessment. The analysis was performed with the use of a multiple­imputation method. The 
number of children with observed data for the 15­month assessment was 35 in the nusinersen group and 19 in the control group, and  
the number of children with imputed data was 49 in the nusinersen group and 23 in the control group.
‡  The least­squares mean change and least­squares mean difference in change between groups were based on an analysis of covariance, 
with group assignment as a fixed effect and with adjustment for each child’s age at screening and the value at baseline.
§  In the final analysis, the following end points were analyzed with the use of a multiple­imputation method: change from baseline in the 
HFMSE score, percentage of children with a change in HFMSE score of at least 3 points, and change from baseline in the RULM score. 
Only children with observed data were included in the other analyses. The number of children with observed data for the 15­month assess­
ment was 66 in the nusinersen group and 34 in the control group, and the number of children with imputed data was 18 in the nusinersen 
group and 8 in the control group.
¶  The percentages and difference (in percentage points) were based on binomial proportions.
‖  This value is an odds ratio instead of a difference. The odds ratio for nusinersen versus control was based on logistic regression, with group 
assignment as a fixed effect and with adjustment for each child’s age at screening and the HFMSE score at baseline.
**  The percentages were based on an exact confidence interval, and the differences (in percentage points) on an exact unconditional confi­
dence interval.
Table 2. Primary and Secondary End Points Assessed at Month 15.*
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epistaxis were at least 5 percentage points higher 
in the nusinersen group than in the control 
group (Table 3). No cases of epistaxis occurred 
in the context of abnormal platelet counts, and 
there were alternative causes that could explain 
these events. The incidences of back pain, head-
ache, and vomiting — known complications of 
lumbar puncture27-29 — were at least 5 percent-
age points higher in the nusinersen group than 
in the control group within 72 hours after the 
assigned procedure (Table S5 in the Supplemen-
tary Appendix). The overall rate of events associ-
ated with lumbar puncture (i.e., back pain, cere-
brospinal f luid leakage, headache, nausea, the 
post–lumbar puncture syndrome, procedural pain, 
procedural nausea, procedural headache, and 
vomiting) within 24, 72, 120, and 168 hours af-
ter the assigned procedure was 9%, 14%, 15%, 
and 15%, respectively, in the nusinersen group and 
3% for each time period in the control group 
(Table S6 in the Supplementary Appendix). There 
were no clinically relevant changes related to 
nusinersen in clinical laboratory test results (see 
the Supplementary Appendix).
Discussion
In the CHERISH trial, among children with later-
onset SMA, significant improvement in motor 
function was observed with nusinersen treat-
ment as compared with a sham procedure. Per-
sons with later-onset SMA and their caregivers 
indicated that stabilization of their current state 
would meet their therapeutic expectations and 
represent a clinically meaningful response.22,30 
In this trial, as in the ENDEAR trial for infan-
tile-onset SMA (most likely to be classified as 
SMA type 1),31 we found that nusinersen had the 
capacity to produce meaningful changes in the 
clinical course of SMA. In this trial, more than 
half the children in the nusinersen group had 
an increase from baseline to month 15 in the 
HFMSE score of at least 3 points (i.e., a clini-
cally meaningful improvement),23 which is un-
common among children with later-onset SMA.32,33 
The final results were consistent with the in-
terim results. The greatest improvements in the 
HFMSE score over the 15-month period were 
observed in younger children and in those who 
received treatment soon after symptom onset. 
Figure 1. Change Over Time in the Hammersmith Functional Motor Scale–
Expanded Score and the Revised Upper Limb Module Score (Final Analysis).
Shown is the least­squares mean change from baseline to the time of each 
trial assessment in the Hammersmith Functional Motor Scale–Expanded 
(HFMSE) score (Panel A) and in the Revised Upper Limb Module (RULM) 
score (Panel B) in the final analysis. HFMSE scores range from 0 to 66, with 
higher scores indicating better motor function19; a change in the HFMSE 
score of at least 3 points is considered to be clinically meaningful.23 RULM 
scores range from 0 to 37, with higher scores indicating better function.25  
I bars indicate standard errors.
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The ENDEAR trial also showed greater improve-
ments in infants who received treatment with 
nusinersen earlier in their disease course than 
in those who received later treatment.31
In the control group, there was improvement 
in the least-squares mean HFMSE score until 
month 6, after which the difference in change 
between the nusinersen group and the control 
group became more apparent. Least-squares 
mean changes in the HFMSE score in the control 
group were largely confined to a ±2-point range 
over the 15-month period, a finding similar to 
observations in a nonambulant natural-history 
cohort over a 12-month period.32 The short-lived 
improvements observed in the control group 
during the first months of the treatment period 
probably resulted from a combination of the 
placebo effect, the learning curve for the assess-
ment of the HFMSE and RULM scores, and ini-
tial developmental gains, particularly in younger 
children.32 Some children in the control group 
had a decrease in the HFMSE score of up to 10 
points, a finding that is consistent with results 
in a recent retrospective study,32 but those treat-
ed with nusinersen had a more stable course.
No new safety concerns were identified.9,10,31 
Back pain and headache are common after lum-
bar puncture, occurring in up to one third of 
children who undergo the procedure,27,34 a rate 
that is consistent with the incidences of these 
adverse events within 72 hours after lumbar 
puncture in the nusinersen group in this trial. 
The overall rate of adverse events associated with 
lumbar puncture observed in the nusinersen 
group in this trial (9 to 15% within 24 to 168 
hours after lumbar puncture) was similar to 
rates reported in the literature (8 to 25%).35-38
This trial had some limitations. For example, 
the strict eligibility criteria (i.e., no severe con-
tractures or scoliosis, outlying HFMSE scores, 
respiratory insufficiency, or reliance on a gastric 
tube) meant that the enrolled population was 
more homogeneous and younger than the popu-
lation that is encountered in the clinical-practice 
setting. In the trial, 16% of the enrolled children 
were 6 years of age or older.
The results we report here are consistent with 
the results of previous open-label studies that 
enrolled children up to 15 years of age. The 
studies showed that nusinersen had positive 
effects in populations of children with SMA 
type 2 or 3 that were broader and more hetero-
Figure 2. Change from Baseline to Month 15 in Individual HFMSE Scores 
According to Age and Disease Duration at Screening (Final Analysis).
Shown is the change from baseline to month 15 in each child’s HFMSE 
score according to age (Panel A) and disease duration (Panel B) at screening 
in the final analysis. Disease duration is a child’s age at screening minus 
the age at symptom onset. The analyses included children in the intention­
to­treat population who did not have missing data for the 15­month assess­
ment (66 in the nusinersen group, and 34 in the control group). The dotted 
lines indicate a 3­point change in the HFMSE score, which is considered to 
be clinically meaningful.23
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Event
Nusinersen 
(N = 84)
Control 
(N = 42)
no. of patients (%)
Any adverse event 78 (93) 42 (100)
Any moderate or severe adverse event 39 (46) 23 (55)
Any severe adverse event 4 (5) 3 (7)
Any serious adverse event 14 (17) 12 (29)
Any adverse event leading to treatment discontinuation 0 0
Any adverse event leading to withdrawal from the trial 0 0
Adverse events with the highest incidence†
Pyrexia 36 (43) 15 (36)
Upper respiratory tract infection‡ 25 (30) 19 (45)
Headache 24 (29) 3 (7)
Vomiting 24 (29) 5 (12)
Back pain 21 (25) 0
Cough‡ 21 (25) 9 (21)
Nasopharyngitis‡ 20 (24) 15 (36)
Serious adverse events with the highest incidence§
Pneumonia‡ 2 (2) 6 (14)
Influenza‡ 0 2 (5)
Respiratory distress‡ 2 (2) 2 (5)
Fecaloma 0 2 (5)
Dehydration 0 2 (5)
Adverse events with an incidence ≥5 percentage points higher 
in the nusinersen group than in the control group¶
Pyrexia 36 (43) 15 (36)
Headache 24 (29) 3 (7)
Vomiting 24 (29) 5 (12)
Back pain 21 (25) 0
Epistaxis 6 (7) 0
*  Investigators rated the severity of each adverse event (mild, moderate, or severe). Moderate adverse events were de­
fined as events that caused discomfort and interrupted the child’s usual daily activities. Severe adverse events were 
 defined as events that caused severe discomfort or incapacitation or had a substantial effect on daily life. Investigators 
reported an adverse event as a serious adverse event if it met the following criterion: any untoward medical occurrence 
that resulted in death or a risk of death, hospitalization or prolonged hospitalization, persistent or substantial disability 
or incapacitation, or a congenital anomaly or birth defect. Reporting of serious adverse events and rating of the severity 
of each adverse event were conducted separately, on the basis of the criteria for each type of adverse event. For partici­
pants who reported more than one adverse event, only one event of the highest severity was counted in the total inci­
dence.
†  The events, classified according to Medical Dictionary for Regulatory Activities (MedDRA) preferred terms, occurred in 
at least 20% of children in either trial group.
‡  The events could plausibly be linked to spinal muscular atrophy.
§  The events, classified according to MedDRA preferred terms, occurred in at least 5% of children in either trial group.
¶  The events were classified according to MedDRA preferred terms. A child was counted only once within each category.
Table 3. Summary of Adverse Events.*
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geneous than the population enrolled in this 
trial.9,17
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